With regard to inflammasome-mediated autoinflammatory diseases, such as FMF, TRAPS, HIDS/MKD, and CAPS, IL-1 blockade has become the most specific and useful treatment, as first-line therapy or when previous conventional anti-inflammatory or immunosuppressive agents are not useful. Here, IL1B is linked to cryopyrin-associated periodic syndrome.